- $228.38m
- $28.36m
- 50
- 37
- 88
- 60
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.04 | ||
Price to Tang. Book | 1.04 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -17.01% | ||
Return on Equity | -10.69% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | 44 | 18.39 | 4.01 | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
XBiotech Inc. is a biopharmaceutical company. The Company is engaged in advancing a pipeline of therapies by harnessing naturally occurring antibodies from patients with immunity to certain diseases. The Company develops True Human monoclonal antibodies for treating a variety of diseases. True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance known as interleukin-1 alpha (IL-1a), which mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma, In almost all chronic and some acute injury scenarios (such as stroke or heart attack).
Directors
- John Simard CHM (58)
- Sushma Shivaswamy CSO (42)
- Queena Han VFN (53)
- Jan-Paul Waldin LED (72)
- Peter Libby IND (74)
- Donald Macadam IND (74)
- W. Thorpe McKenzie IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- September 23rd, 2005
- Public Since
- April 15th, 2015
- No. of Shareholders
- 11
- No. of Employees
- 82
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 30,450,881
- Address
- 5217 WINNEBAGO LANE, AUSTIN, 78744
- Web
- Phone
- +1 5123862900
- Auditors
- Whitley Penn LLP
Upcoming Events for XBIT
XBiotech Inc Annual Shareholders Meeting
Q2 2024 XBiotech Inc Earnings Release
Similar to XBIT
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 18:24 UTC, shares in XBiotech are trading at $7.50. This share price information is delayed by 15 minutes.
Shares in XBiotech last closed at $7.50 and the price had moved by +130.77% over the past 365 days. In terms of relative price strength the XBiotech share price has outperformed the S&P500 Index by +75.08% over the past year.
The overall consensus recommendation for XBiotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
XBiotech does not currently pay a dividend.
XBiotech does not currently pay a dividend.
XBiotech does not currently pay a dividend.
To buy shares in XBiotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $7.50, shares in XBiotech had a market capitalisation of $228.38m.
Here are the trading details for XBiotech:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: XBIT
Based on an overall assessment of its quality, value and momentum XBiotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like XBiotech. Over the past six months, its share price has outperformed the S&P500 Index by +42.55%.
As of the last closing price of $7.50, shares in XBiotech were trading +52.26% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The XBiotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.50.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
XBiotech's management team is headed by:
- John Simard - CHM
- Sushma Shivaswamy - CSO
- Queena Han - VFN
- Jan-Paul Waldin - LED
- Peter Libby - IND
- Donald Macadam - IND
- W. Thorpe McKenzie - IND